Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

226.53 +2.58 (+1.15%)
Streaming Delayed Price Updated: 12:49 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 495,569
Open 225.95
Bid (Size) 226.35 (40)
Ask (Size) 226.71 (40)
Prev. Close 223.95
Today's Range 222.70 - 226.99
52wk Range 197.81 - 495.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on an annualized basis producing an average annual return of 15.23%. Currently, Alnylam Pharmaceuticals... 
Via Benzinga
News headline image
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-43.4%
-43.4%
1 Month
-21.4%
-21.4%
3 Month
-22.3%
-22.3%
6 Month
-29.7%
-29.7%
1 Year
-47.3%
-47.3%

More News

Read More
News headline image
Alnylam (ALNY) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation ↗
Via Chartmill
Alnylam Pharmaceuticals (NASDAQ:ALNY) Plunges After Q2 Revenue Miss and Lowered Full-Year Guidance ↗
Via Chartmill
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth ↗
Via Chartmill
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock ↗
Via Chartmill
News headline image
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
Alnylam Pharmaceuticals (NASDAQ:ALNY): An Affordable Growth Stock with Explosive Momentum and a Reasonable Price ↗
Via Chartmill
News headline image
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Here are the top movers in Thursday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Alnylam Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
What Happens to Stocks After Joining the Nasdaq-100 (History Has a Clear Answer) ↗
Via The Motley Fool
Topics Artificial Intelligence Electric Vehicles Initial Public Offering
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Via MarketBeat
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Via The Motley Fool

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 226.53
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 08/13/26 12:49 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 26.92B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 27B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.